Taiwan: PharmaEssentia raises US$462.7m from upsized GDS

By
Nick Herbert
-

PharmaEssentia Corp, a fully integrated biopharmaceutical company has raised US$462.7m from an upsized global depositary share (GDS) offering, according to IFR. The issuance is a large one to digest, says Ethan Aw of Aequitas Research in a note published on SmartKarma, as it represents over 17 days of three month average daily volumes. Nevertheless, the…

You must be a HMI Subscriber to view this content.

Subscribe Now »

Previous articleDubai Leads, Industry Innovates
Next articleMDU appoints head of legal services
Nick Herbert
Nick Herbert has over 30 years’ experience in the financial markets, as both a practitioner and journalist. He started work as an investment banker in London, before joining International Financing Review (IFR) to report on debt capital markets and derivatives. He moved to Singapore in 2000 to manage IFR’s financial markets editorial team throughout Asia, before returning to London in 2009 to take up the position of Publisher for Reuters Capital Markets Publications. For the last five years he has been covering global capital markets, ESG finance and healthcare markets on a freelance basis.

RELATED ARTICLESMORE FROM AUTHOR